Ophthalmology and Therapy最新文献

{"title":"Refractive and Visual Outcomes of SmartSight NOVA Refractive Lenticule Extraction for Myopia and Myopic Astigmatism at 3 Months: a Retrospective Case Series.","authors":"Ji Eun Keum, Tae Keun Yoo, Jong-Chan Kim, Jun-Hyung Kim","doi":"10.1007/s40123-026-01437-7","DOIUrl":"10.1007/s40123-026-01437-7","url":null,"abstract":"<p><strong>Introduction: </strong>SmartSight NOVA using the ATOS platform (SCHWIND eye-tech-solutions GmbH, Kleinostheim, Germany) is a refractive lenticule extraction method with CenTrax-assisted centration. We hypothesized that SmartSight NOVA would provide safe, effective, and predictable 3-month outcomes for myopia and myopic astigmatism while maintaining favorable positional stability relative to the preoperative vertex-centered reference and acceptable higher-order aberration profiles.</p><p><strong>Methods: </strong>This retrospective single-center case series included 84 eyes of 42 patients treated with SmartSight NOVA for myopia and myopic astigmatism. Standard refractive surgery outcome analyses were performed at 1 and 3 months, including visual acuity, manifest refraction, and stability. Higher-order aberrations, chord μ subgroup analyses, and postoperative center-coordinate stability relative to the preoperative position were also assessed.</p><p><strong>Results: </strong>No clinically significant intraoperative or postoperative complications were observed during the 3-month follow-up. Preoperative manifest spherical equivalent was -3.70 ± 1.21 D. At 3 months, mean postoperative uncorrected distance visual acuity was 0.006 ± 0.020 logarithm of the minimum angle of resolution (logMAR), and postoperative manifest sphere, cylinder, and spherical equivalent were 0.021 ± 0.311 D, -0.327 ± 0.280 D, and -0.143 ± 0.336 D, respectively. Spherical equivalent was within ± 0.50 diopters (D) in 81.0% of eyes at 1 month and 89.3% at 3 months, and within ± 1.00 D in 100.0% of eyes at both visits. Postoperative refractive astigmatism was ≤ 0.50 D in 86% of eyes and ≤ 1.00 D in 100% of eyes at 3 months. No eyes lost two or more lines of corrected distance visual acuity. Induced higher-order aberrations did not differ significantly among preoperative chord μ groups. Mean displacement magnitude was 0.049 ± 0.028 mm, and 92.9% of eyes were within 0.10 mm of the preoperative position.</p><p><strong>Conclusions: </strong>SmartSight NOVA showed favorable early clinical outcomes at 3 months, with good visual and refractive performance, low residual astigmatism, limited higher-order aberration induction, and small postoperative displacement relative to the preoperative vertex-centered reference in most eyes.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2713-2728"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six-Month Real-World Data in Macular Edema Due to Retinal Vein Occlusion Treated with Faricimab: Swiss Retina Research Network Report.","authors":"Katharina Heck, Katja Hatz, Marco Cattaneo, Isabel Pfister, Simon Magnin, Ludovico Ruscitti, Isabel Stasik, Anne Tillmann, Marat Shamshiev, Joseph Fang, Andreas Weinberger, Sandrine A Zweifel, Justus G Garweg, Chiara M Eandi, Gabriela Grimaldi, Marion R Munk, Gabor M Somfai, Aude Ambresin, Nicolas Feltgen","doi":"10.1007/s40123-026-01442-w","DOIUrl":"10.1007/s40123-026-01442-w","url":null,"abstract":"<p><strong>Introduction: </strong>Faricimab has been shown to be effective for treatment of macular edema (ME) due to retinal vein occlusion (RVO). So far, there is only limited evidence in real-life settings and hard-to-treat cases.</p><p><strong>Methods: </strong>This multicenter, retrospective study evaluated patients with branch or central (including hemi-central) RVO treated with a faricimab treat-and-extend regimen with at least 6 months of follow-up (FU). Data included best-corrected visual acuity (BCVA), center-point retinal thickness (CRT), central subfield thickness (CST), presence of intra- and subretinal fluid in the 1, 3, and 6 mm Early Treatment Diabetic Retinopathy Study (ETDRS) grid zones, number of injections, and adverse events at baseline and at 1, 3-4, and 6 months of faricimab therapy. Pretreated eyes were additionally evaluated at predefined time points of the pretreatment period.</p><p><strong>Results: </strong>A total of 112 eyes from 111 patients, including 13 treatment-naive and 99 pretreated eyes, were included. BCVA improved in treatment-naïve eyes from 0.46 ± 0.28 logarithm of the minimum angle of resolution (logMAR) at baseline to 0.32 ± 0.28 logMAR 6 months later (p = 0.041). BCVA remained stable in pretreated eyes (0.20 ± 0.25 vs. 0.21 ± 0.29 logMAR; p = 0.7). CRT and CST improved in both groups: in treatment-naïve eyes, CRT from 522 to 267 µm (p < 0.001) and CST from 467 to 301 µm (p = 0.032); in pretreated eyes, CRT from 275 to 253 µm (p = 0.009) and CST from 315 to 293 µm (p = 0.001). Significant resolution in retinal fluid was shown in the central 1 mm (p ≤ 0.014), 3 mm (p ≤ 0.013), and 6 mm zones (p ≤ 0.013) of the ETDRS grid in both groups. Over 6 months, treatment-naïve and pretreated eyes received a mean of 5 ± 1 injections. One systemic adverse event and no intraocular inflammation were recorded during FU.</p><p><strong>Conclusion: </strong>This study demonstrates good real-world efficacy with significant drying and promising safety profile of faricimab in eyes with ME due to RVO, including a high proportion of hard-to-treat cases, over a 6-month period.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2643-2657"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fast Progressors in Primary Open-Angle Glaucoma: A 5-Year Visual Field Index-Based Classification in a Real-World Cohort.","authors":"Chengjie Feng, Jing Sun, Tingting Liu, Jingjing Zhao, Xiang Fan, Jing Hong, Lingling Wu","doi":"10.1007/s40123-026-01417-x","DOIUrl":"10.1007/s40123-026-01417-x","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to investigate the effect of visual field index (VFI) of identifying especially \"fast visual field (VF) progressors\" in patients with primary open angle glaucoma (POAG) and to analyze the risk factors.</p><p><strong>Methods: </strong>Fast progression was defined as VFI decline worse than -4.6%/year or mean deviation (MD) worse than -1 decibel (dB)/year. Moderately rapid progression (MRP) was defined using cohort-derived cutoffs (VFI worse than -1.016%/year; MD worse than -0.44 dB/year). Proportions of fast progression and MRP were compared between VFI- and MD-based criteria and across baseline disease stages. Longitudinal VFI change was further analyzed as a continuous outcome using linear mixed-effects models (LMM) with random intercepts and slopes for eyes nested within patients.</p><p><strong>Results: </strong>A total of 162 participants (315 eyes) were included; 94 (58.02%) were male and 68 (41.98%) were female. VFI indicated a fast progression rate of 0.92% and MRP rate of 20.63%, whereas MD yielded 2.75% and 23.49%, respectively. The proportion of eyes classified as VFI-defined MRP increased markedly with advancing disease stage (p < 0.001). MD-confirmed MRP showed a concordant stage-dependent trend but did not reach statistical significance. In multivariable analysis, worse baseline MD, thinner central corneal thickness, lower spherical equivalent, and older age were independently associated with a steeper annual VFI decline.</p><p><strong>Conclusions: </strong>In this long-term treated POAG cohort, VFI-defined fast progression was rare; however, VFI-based criteria provided statistically significant stage-dependent discrimination of clinically relevant progression. The results support incorporating longitudinal VFI modeling into routine-care datasets to better identify eyes at higher risk of meaningful functional loss over time.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2627-2641"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripapillary Retinal Nerve Fibre and Ganglion Cell Layer Changes Following Intravitreal Aflibercept 8 mg Therapy in Neovascular Age-Related Macular Degeneration: A Longitudinal OCT Study.","authors":"Giulio Volpe, Matteo Bonanata, Arianna Peyla, Ludovico Ruscitti, Veronika Eggarter, Martina Pache, Arianna Paris, Moreno Menghini, Gabriela Grimaldi","doi":"10.1007/s40123-026-01431-z","DOIUrl":"10.1007/s40123-026-01431-z","url":null,"abstract":"<p><strong>Introduction: </strong>Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is the standard of care for neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases. However, transient post-injection intraocular pressure elevations have raised concerns regarding potential cumulative effects on inner retinal structures, including the peripapillary retinal nerve fibre layer (pRNFL) and macular ganglion cell-inner plexiform layer (mGCIP). As longitudinal evidence on the neuro-retinal structural safety of higher-dose formulations such as aflibercept 8 mg remains limited, this study evaluated 12-month changes in pRNFL and mGCIP thickness following intravitreal aflibercept 8 mg.</p><p><strong>Methods: </strong>This single-centre, observational longitudinal cohort study included patients with nAMD treated with intravitreal aflibercept 8 mg or aflibercept 2 mg. Patients receiving aflibercept 8 mg were prospectively enrolled, while patients treated with 2 mg aflibercept were retrospectively identified. Spectral-domain optical coherence tomography was used to assess pRNFL and mGCIP thickness at baseline and at 3, 6 and 12 months. Longitudinal within-eye changes relative to baseline were analysed, alongside inter-eye comparisons with fellow untreated eyes and between-treatment group comparisons at 12 months.</p><p><strong>Results: </strong>Thirty-eight eyes from 35 patients were included. In eyes treated with aflibercept 8 mg, mGCIP thickness remained stable throughout follow-up, with no significant changes at 3, 6 or 12 months compared with baseline. At 12 months, mGCIP thickness was comparable between aflibercept 8 mg-treated eyes and fellow untreated eyes, as well as between aflibercept 8 mg and aflibercept 2 mg-treated eyes. Similarly, pRNFL thickness showed no significant global or sectoral changes over 12 months and did not differ between treatment groups.</p><p><strong>Conclusion: </strong>Over 12 months of follow-up, intravitreal aflibercept 8 mg was not associated with significant thinning of pRNFL or mGCIP thickness, supporting its neuro-retinal structural safety in routine clinical practice.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2659-2668"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148308913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal Vascular Features and Risk of Colorectal Cancer Incidence and Mortality: A Population-Based Cohort Study.","authors":"Wenli Zhang, Lei Liu, Min-Er Zhong, Cong Li, Yun Ren, Zhenchao Du, Yan Wang, Jingyan Peng, Ying Yao, Xue He, Heng Li, Zhishen Peng, Tengda Huang, Yong Li, Honghua Yu, Danli Shi, Xiaohong Yang","doi":"10.1007/s40123-026-01418-w","DOIUrl":"10.1007/s40123-026-01418-w","url":null,"abstract":"<p><strong>Introduction: </strong>Colorectal cancer (CRC) screening remains limited by invasiveness and suboptimal sensitivity of current methods. Retinal microvasculature, a noninvasive window into systemic vascular health, may reflect CRC-associated angiogenesis and inflammation. We investigated whether artificial intelligence (AI)-derived retinal vascular features (RVFs) are associated with CRC risk and prognosis.</p><p><strong>Methods: </strong>This analysis included UK Biobank participants with baseline fundus imaging. Multidimensional RVFs, including tortuosity, branching angle, caliber, density, and complexity, were quantified using the Retina-based Microvascular Health Assessment System (RMHAS). Associations of RVFs with incident CRC and mortality among patients with CRC were evaluated using univariable and multivariable Cox regression models.</p><p><strong>Results: </strong>Among 55,798 participants (mean age 55.47 ± 8.09 years; 55.07% female), over a median follow-up of 11.32 years, 652 incident CRC cases (including 488 colon cancers and 260 rectal cancers) and 171 post-CRC deaths were documented. After full adjustment, four RVFs showed significant associations with CRC risk: increased arterial tortuosity (hazard ratio [HR] 1.03, 95% confidence interval [CI] 1.01-1.06), wider venular minimum branching angle (HR 1.09, 95% CI 1.02-1.17), smaller arterial maximum branching coefficient (HR 0.90, 95% CI 0.82-0.99), and reduced venular angular asymmetry (HR 0.89, 95% CI 0.82-0.96). For mortality, higher venular tortuosity (HR 1.14, 95% CI 1.00-1.31) and increased arterial maximum length diameter ratio (HR 1.16, 95% CI 1.01-1.32) were associated with elevated risk, whereas venular caliber (HR 0.81, 95% CI 0.67-0.98) and venular length diameter ratio (HR 0.82-0.84) were inversely associated with mortality. Distinct RVF patterns were observed between colon and rectal cancers.</p><p><strong>Conclusion: </strong>Specific AI-derived RVFs were independently associated with CRC risk, its subtypes, and mortality. These findings suggest that retinal microvascular changes may reflect systemic processes related to carcinogenesis and point to the potential of retinal imaging as a noninvasive tool for CRC risk stratification.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2695-2711"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148361795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal Faricimab for Retinal Vein Occlusion: Real-World Outcomes from the Multicenter FARTURK-RVO Study in Türkiye.","authors":"Fevzi Akkan, Ebru Görgün, Burak Erden, Yavuz Kamil Bardak, Nigar Şerif, Mahmut Öztürk, Erkan Çelik, Selim Bölükbaşı, Şefik Can İpek, Tahsin Uzundede, Gamze Karataş, Murat Karapapak, Ece Özal, Osman Murat Uyar, Doğukan Cömerter, Mehmet Numan Alp, Serhat Ermiş, Anıl Korkmaz, Murat Arıcı, Mehmet Egemen Karataş, Nursal Melda Yenerel, Halil Özgür Artunay, Ecem Önder-Tokuç, Veysel Levent Karabaş, Melih Ünal, Ziya Kapran, Hakan Özdemir, Akın Çakır","doi":"10.1007/s40123-026-01436-8","DOIUrl":"10.1007/s40123-026-01436-8","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to evaluate the real-world efficacy and safety of intravitreal faricimab for macular edema (ME) secondary to retinal vein occlusion (RVO) across a multicenter cohort with up to 52 weeks of follow-up.</p><p><strong>Methods: </strong>Data from 17 centers across Türkiye were retrospectively analyzed between 22 November 2024 and 1 March 2026. Patients with branch RVO (BRVO) or central RVO (CRVO) complicated by ME who received at least one intravitreal faricimab injection and had complete ophthalmic and optical coherence tomography (OCT) data with a minimum 4-week follow-up were included. Demographics, diagnosis, prior treatments, best-corrected visual acuity (BCVA; decimal converted to logMAR), central macular thickness (CMT), intraocular pressure (IOP), injection number, follow-up duration, and ocular/systemic adverse events were recorded at baseline, day 7, monthly after each of the first three injections, and at the final visit.</p><p><strong>Results: </strong>A total of 70 patients (37 BRVO [52.9%], 33 CRVO [47.1%]) were included, with a mean follow-up of 23.69 ± 8.54 weeks; 44 (62.8%) were treatment-naïve and 26 (37.2%) were switch patients. When comparing baseline and final visits, treatment-naïve patients showed a mean CMT reduction of 306.9 ± 231.3 µm (from 594.1 ± 206.9 µm at baseline to 287.2 ± 89.9 µm at final visit; p < 0.001), while switch patients demonstrated a mean CMT reduction of 290.6 ± 114.3 µm (from 562.1 ± 107.3 to 271.5 ± 90.7 µm; p < 0.001). The mean logMAR BCVA gain was 0.77 (p < 0.001) in naïve and 0.38 (p < 0.001) in switch patients. IOP remained stable throughout, and no serious ocular or systemic adverse events were recorded.</p><p><strong>Conclusions: </strong>Faricimab demonstrated rapid anatomical and functional improvements in the RVO cohort, evident as early as day 7 after the initial injection. These findings support faricimab as a potent and reliable therapeutic option across both RVO subtypes in routine clinical practice.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2607-2625"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Summary of Research: Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.","authors":"Scott M Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, Ali Mojebi, Sam Keeping, Keith Chan, Theodore Leng, Nimesh A Patel","doi":"10.1007/s40123-026-01434-w","DOIUrl":"10.1007/s40123-026-01434-w","url":null,"abstract":"<p><p>This is a summary of the original research article \"Aflibercept 8 mg versus Faricimab Treat‑and‑Extend for Diabetic Macular Edema or Neovascular Age‑Related Macular Degeneration: A Bayesian Fixed‑Effect Network Meta‑analysis of Clinical Trials.\" Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are eye diseases that can be treated with anti-vascular endothelial growth factor (anti-VEGF) therapies. As these therapies are given by injections into the eye, reducing the number of injections could reduce the treatment burden on patients and healthcare providers. Aflibercept 8 mg and faricimab treat-and-extend (T&E) may enable longer dosing intervals compared with other available anti-VEGF therapies for patients with DME and nAMD; however, they have not been compared against each other directly in clinical trials. This study used a statistical method called a network meta-analysis (NMA) to compare aflibercept 8 mg and faricimab T&E by synthesizing data from clinical trials, enabling an indirect comparison in the absence of head-to-head studies. Outcomes included the mean number of injections, changes in vision [best-corrected visual acuity (BCVA)] and changes in macula thickness [central subfield thickness (CST)]. CST should reduce if the treatment is working. On the basis of indirect comparison of available clinical trial data, this exploratory study found that there were significantly fewer injections with aflibercept 8 mg treatment compared with faricimab T&E over 2 years, for both patients with DME and nAMD, and there were no significant differences between the two medications for BCVA or CST changes. NMAs are based on indirect comparisons and therefore have limitations, and clinical trials or real-world studies would be required to confirm these conclusions. Please refer to the original article for further details on the methods and limitations of this analysis.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2515-2518"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148302532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Effects of Phacoemulsification with Goniosynechialysis in Angle-Closure Glaucoma: A 2-Year Prospective Cohort Study.","authors":"Feng Gao, Jiajian Wang, Xiangmei Kong, Li Wang, Shaohong Qian, Xinghuai Sun, Yuhong Chen","doi":"10.1007/s40123-026-01426-w","DOIUrl":"10.1007/s40123-026-01426-w","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of this study was to compare long-term effect of phacoemulsification combined with goniosynechialysis (Phaco-GSL) in patients with acute primary angle-closure glaucoma (APACG) and those with chronic primary angle-closure glaucoma (CPACG), and to evaluate the influencing factors of the surgical prognosis.</p><p><strong>Methods: </strong>In this prospective cohort study, patients with APACG or CPACG who underwent Phaco-GSL at the glaucoma clinics of Eye and ear, nose, and throat (ENT) Hospital were recruited consecutively from January 2019 to December 2022. Standardized 2-year follow-ups assessed baseline characteristics and surgical outcomes. The cumulative success rates and influencing factors of surgical prognosis were analyzed.</p><p><strong>Results: </strong>A total of 213 patients were enrolled, including 116 patients (116 eyes) with APACG and 97 patients (97 eyes) with CPACG. The average age was 64.5 ± 7.2 years and 153 (71.8%) patients were women. The complete success rates at 2 years were 72.4% in the acute group and 65.0% in the chronic group (P = 0.04). The qualified success rates at 2 years were 81.9% in the acute group and 81.4% in the chronic group (P = 0.44). Baseline mean deviation, anterior chamber depth (ACD), and glaucoma type were identified as independent predictors of surgical outcomes in the overall cohort. In subgroup analyses, a longer duration of elevated intraocular pressure showed a trend toward poorer surgical prognosis in acute PACG, whereas shallower ACD was associated with poorer outcomes in chronic PACG.</p><p><strong>Conclusions: </strong>Phaco-GSL demonstrated significant benefits for both APACG and CPACG, with more pronounced effects for APACG. Identifying patients with prognostic factors preoperatively provides valuable insights for better assessing the outcomes of GSL surgery in PACG.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2587-2605"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148295842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Life 1-Year Results and Predictors of Visual Outcome with Intravitreal Faricimab for Treatment of Exudative Neovascular Age-Related Macular Degeneration.","authors":"Federico Beretta, Giovanni Scalabrin, Edoardo Balduzzi, Stefano Puligheddu, Francesco Bandello, Riccardo Sacconi, Giuseppe Querques","doi":"10.1007/s40123-026-01453-7","DOIUrl":"10.1007/s40123-026-01453-7","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to report 1-year real-world outcomes of faricimab for the treatment of macular neovascularization secondary to age-related macular degeneration (nAMD). Early predictors of functional outcome were investigated.</p><p><strong>Methods: </strong>This was a retrospective, longitudinal study including 132 eyes with nAMD (27% treatment-naïve, 73% switchers) treated with faricimab following a treat-and-extend protocol. Primary outcomes were best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes at 1-year follow-up. Secondary outcomes included possible early predictors of 1-year functional outcomes. Early predictors were investigated at the baseline and after the loading phase.</p><p><strong>Results: </strong>After the loading phase, both BCVA (from 0.40 ± 0.33 to 0.35 ± 0.34 LogMAR) and CMT (from 403 ± 135 to 317 ± 108 um) improved significantly (p = 0.014 and p > 0.001 respectively). At 1 year, only CMT reduced significantly (from 403 ± 135 to 317 ± 114 um, p < 0.001), and 36% of eyes were defined as good visual responders (≥ 5 ETDRS letters gain). Predictors of good response were lower BCVA and absence of type 3 macular neovascularization (MNV) at baseline and lower CMT after loading phase. Approximately 60% of patients achieved ≥ Q12-week dosing. Treatment-naïve patients achieved higher extension rates (82% ≥ Q12). No cases of intraocular inflammation were observed.</p><p><strong>Conclusions: </strong>In our real-world practice, faricimab effectively controls nAMD, offering significant anatomical benefits and visual stability with extended dosing intervals. Approximately 80% of treatment-naïve patients maintained ≥ Q12-week schedules. Early anatomical response, defined by reduction in CMT and absence of exudative signs on structural optical coherence tomography (OCT), emerged as a clinically relevant prognostic factor for 1-year outcomes.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2813-2824"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424026/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148397212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aflibercept 24-Month Outcomes in Diabetic Macular Edema With and Without Prior Macular Laser Therapy: Data from the Fight Retinal Blindness! Registry.","authors":"Luca Timoceanu, Sarah Steinmann, Mark C Gillies, Daniel Barthelmes","doi":"10.1007/s40123-026-01449-3","DOIUrl":"10.1007/s40123-026-01449-3","url":null,"abstract":"<p><strong>Introduction: </strong>We evaluated 24-month real-world outcomes of intravitreal aflibercept 2 mg for diabetic macular edema (DME) in treatment-naive eyes and eyes previously treated with macular thermal laser photocoagulation.</p><p><strong>Methods: </strong>This retrospective observational cohort study analyzed data from a prospectively designed treatment outcomes registry. We described outcomes separately in treatment-naive eyes and eyes previously treated with macular thermal laser photocoagulation, all of which received intravitreal aflibercept 2 mg for DME in routine clinical practice. Given the small number of eyes with prior macular laser, findings in this subgroup were considered descriptive and exploratory. The main functional outcome was change in visual acuity (VA) from baseline at 6, 12, and 24 months. The main anatomical outcome was change in central subfield thickness (CST) from baseline at the same time points. Secondary outcomes were injection and visit burden, changes in center-involving clinically significant macular edema activity, time to additional macular laser treatment, and ocular adverse events.</p><p><strong>Results: </strong>The cohort included 122 eyes from 78 patients: 110 treatment-naive eyes and 12 eyes with prior macular laser. In treatment-naive eyes, mean VA improved from baseline by 5.5, 5.0, and 5.5 letters at 6, 12, and 24 months, respectively. Mean CST decreased by 105.9 µm, 90.4 µm, and 97.1 µm, respectively. In eyes with prior macular laser, changes in VA were not statistically significant at any follow-up point. CST decreased significantly at 6 months (-36.5 µm) and 12 months (-37.5 µm), but not at 24 months (-26.1 µm). By month 24, the median number of injections was 12 in treatment-naive eyes and 11 in eyes with prior macular laser. Additional macular laser was rarely needed, and ocular adverse events were rare.</p><p><strong>Conclusions: </strong>In routine clinical care, intravitreal aflibercept 2 mg for DME was associated with sustained anatomical improvement and modest, largely stable visual gains over 24 months, particularly in treatment-naive eyes. These findings support favorable real-world outcomes with aflibercept, although subgroup findings in eyes with prior macular laser should be interpreted cautiously.</p>","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"2797-2811"},"PeriodicalIF":4.2,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13424033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148387925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}